MUMBAI, India, Aug. 10 -- Intellectual Property India has published a patent application (202647091406 A) filed by The United States Of America, As Represented By The on July 28, 2026, for Novel Compositions Of Matter Comprising Proteins That Incorporate Pfs230 Or Pvs230 Domain 1 (pfs230d1 Or Pvs230d1) At The N-Terminus, Malaria Vaccine Antigens, And Their Use.
Inventors include Duffy, Patrick E.; and Renn, Jonathan P..
The application for the patent was published on July 31, 2026, under issue no. 31/2026.
Abstract: The invention provides a protein comprising, from amino- to carboxy-termini: (a) a first polypeptide domain derived from the Pfs230 domain 1 (Pfs230D1) of Plasmodium falciparum or the Pvs230 domain 1 (Pvs230D1) of Plasmodium vivax, (b) an optional linker domain, and (c) a second polypeptide domain, which can be a 6-Cys polypeptide, wherein the fusion protein is not the native Pfs230 or Pvs230 protein. The invention also provides nucleic acids encoding the inventive protein, genetic vectors comprising such nucleic acid, cells comprising the protein, nucleic acid or vector, compositions comprising such reagents. The invention also provides a method for vaccinating a subject using the inventive protein and composition and the use of the inventive protein and composition in connection with such a method.
Disclaimer: Curated by HT Syndication.
